Compare Davita Inc (DVA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Sony Group Corp — how do they compare? Davita Inc trades at $229.39 (market cap $14.92B), while Sony Group Corp trades at $20.78 (market cap $122.79B). The key difference: Sony Group Corp is far larger — about 8.2× Davita Inc's market cap, and Sony Group Corp pays a 0.76% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SONY | |
|---|---|---|
Market Cap | $14.92B | $122.79B |
Sector | Health | Technology |
52-Week High | $235.71 | $30.26 |
52-Week Low | $103.87 | $19.32 |
Enterprise Value | $27.47B | $119.28B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Sony trades at $20.68, down 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong operating cash flow of $2.32 trillion for 2025 and maintains solid valuation metrics including a P/E of 19.51. Recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook remains mixed with analyst consensus strongly bullish (69% buy ratings) but near-term earnings volatility. Key opportunities include digital transformation and financial services expansion, while risks involve execution of digital strategy and projected net income decline to -$326.9 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
